Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis

被引：0
|
作者：
de Seze, J. [1 ]
Montalban, X. [2 ]
McDougall, F. [3 ]
Sauter, A. [3 ]
Deol-Bhullar, G. [3 ]
Wolinsky, J. [4 ]
机构：
[1] Univ Hosp Strasbourg, Strasbourg, France
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1279
引用
收藏
页码：677 / 678
页数：2
相关论文
共 50 条
  • [1] Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis
    de Seze, Jerome
    Montalban, Xavier
    McDougall, Fiona
    Julian, Laura
    Sauter, Annette
    Deol-Bhullar, Gurpreet
    Wolinsky, Jerry
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 84 - 84
  • [2] Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study
    Montalban, X.
    Hemmer, B.
    Rammohan, K.
    Giovannoni, G.
    de Seze, J.
    Bar-Or, A.
    Arnold, D. L.
    Sauter, A.
    Kakarieka, A.
    Masterman, D.
    Chin, P.
    Garren, H.
    Wolinsky, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 781 - 782
  • [3] Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study
    Montalban, Xavier
    Hemmer, Bernhard
    Rammohan, Kottil
    Giovannoni, Gavin
    De Seze, Jerome
    Bar-Or, Amit
    Arnold, Douglas
    Sauter, Annette
    Masterman, Donna
    Fontoura, Paulo
    Garren, Hideki
    Chin, Peter
    Wolinsky, Jerry
    [J]. NEUROLOGY, 2016, 86
  • [4] Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS)
    Montalban, X.
    Arnold, D.
    Bar-or, A.
    de Seze, J.
    Giovannoni, G.
    Hemmer, B.
    Rammohan, K.
    Mairon, N.
    Chin, P.
    Fontoura, P.
    Garren, H.
    Masterman, D.
    Sauter, A.
    Wolinsky, J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 410 - 410
  • [5] Phase III Study of Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis: ORATORIO Study Design
    Montalban, Xavier
    Wolinsky, Jerry
    Yin, Ming
    Leppert, David
    Glanzman, Robert
    Chin, Peter
    [J]. NEUROLOGY, 2011, 76 (09) : A319 - A320
  • [6] Use of Patient-Reported Outcomes in Randomized, Double-Blind, Placebo-Controlled Clinical Trials
    Dinan, Michaela A.
    Compton, Kate L.
    Dhillon, Jatinder K.
    Hammill, Bradley G.
    DeWitt, Esi Morgan
    Weinfurt, Kevin P.
    Schulman, Kevin A.
    [J]. MEDICAL CARE, 2011, 49 (04) : 415 - 419
  • [7] Patient-Reported Outcomes as a Component of the Primary Endpoint in a Double-Blind, Placebo-Controlled Trial in Advanced Pancreatic Cancer
    Eckhardt, S. Gail
    De Porre, Peter
    Smith, David
    Maurel, Joan
    Steward, William P.
    Bouche, Olivier
    van de Velde, Helgi
    Michiels, Bart
    Bugat, Roland
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2009, 37 (02) : 135 - 143
  • [8] Rituximab in patients with primary progressive multiple sclerosis: demographics in a Phase II/III randomised, double-blind, placebo-controlled multicentre trial
    Hawker, K.
    Freedman, M. S.
    O'Connor, P.
    Calabresi, P.
    Antel, J. P.
    Pallitch, H.
    Simon, J.
    Hauser, S.
    Sarkar, N.
    Agarwal, S.
    Langer-Gould, A.
    Smith, C.
    [J]. MULTIPLE SCLEROSIS, 2007, 13 : S165 - S165
  • [9] Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
    Lublin, Fred
    Miller, David H.
    Freedman, Mark S.
    Cree, Bruce A. C.
    Wolinsky, Jerry S.
    Weiner, Howard
    Lubetzki, Catherine
    Hartung, Hans-Peter
    Montalban, Xavier
    Uitdehaag, Bernard M. J.
    Merschhemke, Martin
    Li, Bingbing
    Putzki, Norman
    Liu, Fonda C.
    Haering, Dieter A.
    Kappos, Ludwig
    [J]. LANCET, 2016, 387 (10023): : 1075 - 1084
  • [10] Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: A double-blind, randomized, placebo-controlled study
    Fagien, Steven
    Cox, Sue Ellen
    Finn, J. Charles
    Werschler, W. Philip
    Kowalski, Jonathan W.
    [J]. DERMATOLOGIC SURGERY, 2007, 33 : S2 - S9
12345